Bortezomib, Dexamethasone, and Rituximab in Untreated Waldenstroms Macroglobulinemia

Clinical trial NCT00832234 · COMPLETED

Trial details

NCT number: NCT00832234
Sponsor: European Myeloma Network B.V.
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Waldenstroms Macroglobulinemia

Start date: 2006-09-01
Primary completion: 2010-06-01
Enrollment: 59

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.